• Schedule 13D/G History

Orca Capital AG - Significant Ownership

Signature - Title
Orca Capital AG - Thomas Konig/Director
Location
Pfaffenhofen, Germany
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Orca Capital AG.

Significant Ownership of Orca Capital AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PHIO Phio Pharmaceuticals Corp. Common Stock, par value $0.0001 per share 9.9% $695K 515K Orca Capital AG Dec 19, 2024
CANF Can-Fite BioPharma Ltd. Ordinary Shares, no par value 9.7% $589M 375M Orca Capital AG Apr 14, 2025
ENVB Enveric Biosciences, Inc. Common Stock, par value $0.01 per share 4.9% $32K -$23K 97K -41.8% Orca Capital AG Jan 31, 2025
LIXT Lixte Biotechnology Holdings, Inc. Common Stock, par value $0.0001 per share 4.5% $134K -$109K 120K -44.8% Orca Capital AG Feb 14, 2025
DWTX Dogwood Therapeutics, Inc. Common Stock, par value $0.0001 per share 3.7% $540K 69.8K Orca Capital AG Mar 14, 2025
SPCB SuperCom Ltd. Ordinary Shares, par value NIS 50 3.6% $881K -$1.05M 125K -54.3% Orca Capital AG Jan 31, 2025
BHAT Blue Hat Interactive Entertainment Technology Ordinary Shares, par value $0.01 per share 0% $0 -$368K 0 -100% Orca Capital AG Jan 13, 2025
VERO Venus Concept Inc. Common Stock, par value $0.001 per share 0% $0 -$190K 0 -100% Orca Capital AG Apr 11, 2025
SGLY Singularity Future Technology Ltd. Common Stock, no par value 0% $0 -$189K 0 -100% Orca Capital AG Jan 31, 2025

Schedules 13D/G Reported by Orca Capital AG:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.